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Background
Cardiac involvement of sarcoidosis hallmarked by inflam-
matory myocardial processes and subsequent fibrotic myo-
cardial alterations is a life threatening condition that
makes early diagnosis favorable. Native T1- as well as
T2-mapping have been proposed as reliable methods to
non-invasively assess diffuse myocardial fibrosis and
edema respectively. Our aim was to examine the value of
both methods for the differentiation between healthy and
diseased myocardium.
Methods
Patients with sarcoidosis who previously underwent a
CMR examination at our hospital were invited for a follow
up scan. The follow up scan performed on a 1.5T Philips
INGENIA scanner comprised a clinically routine CMR-
protocoll with additional T1- and T2-mapping in midven-
tricular short axis (SA) slice. T1-mapping was performed
using MOdified Look Locker Inversion Recovery Imaging
(3-3-5 MOLLI) and T1-relaxation times were quantified
within the septal myocardium (CONSEPT-approach). For
T2 mapping an optimized 6-echo gradient spin echo
(GraSE) sequence was used measuring T2 relaxation times
within the whole SA slice. CMR exams were classified as
“cardiac involvement” if at least one of the following
pathologies occured: pathological relative enhancement,
late enhancement findings consistent with (post-) inflam-
matory changes, myocardial edema, pericardial effusion.
According to CMR results patients were divided into 4
different groups: group 1 (n = 10): patients with positive
findings in both exams, group 2 (n = 6): patients with posi-
tive findings only in the initial exam; group 3 (n = 8):
patients with sarcoidosis but inconspicuous initial CMR
exam and group 4 (n = 20): a control group of healthy age
matched volunteers with no medical history of sarcoidosis
or cardiac disease.
Results
Results are shown in Table 1.
T1 relaxation times were significantly longer in patients
with positive CMR findings in both the initial examination
and the follow-up scan (group 1) in comparison to all
other groups (p < 0,05). However no significant difference
in T1 relaxation time could be revealed in patients with
history of cardiac involvement of sarcoidosis (group 2) as
well as patients with sarcoidosis but no CMR findings
(group 3; p < 0,05). No significant difference in T2 relaxa-
tion times could be revealed between all 4 groups
(p < 0,05).
Conclusions
Patients with consistent cardiac involvement of sarcoidosis
have significantly increased T1 relaxation times as a sign
of diffuse cardiac fibrosis whereas no relation between
diffuse myocardial edema and cardiac involvement of
sarcoidosis could be revealed.
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Table 1
Age (years) LVEDV (ml) IVSD (mm) EF (%) T1 (ms) T2 (ms)
Group 1 (n=10) 51,80 ± 28,28 134,55 ± 42,42 9,11 ± 0,71 58,78 ± 7,07 1009,30 ± 13,44 (p <0,05) 54 ± 1,41
Group 2 (n=6) 54,33 ± 5,66 117 ± 21,92 9,20 ± 1,06 60,8 ± 18,38 988 ± 10,61 54,17 ± 2,12
Group 3 (n=8) 55,13 ± 11,31 110,57 ± 16,26 9,69 ± 0,71 66,50 ± 1,41 1001,86 ± 0,71 54,50 ± 2,08
Group 4 (n=20) 50,60 ± 31,82 150,40 ± 61,52 9,96 ± 0,71 62,55 ± 4,24 957,65 ± 15,56 52,95 ± 4,95
Patient characteristics as well as T1 and T2 relaxation times.
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